Net Income: Company's net profit or loss after all revenues, income items, and expenses have been accounted for. Because this figure is given after preferred dividend expense, it is the net income value allotted to common shareholders.
Inhibikase Therapeutics, Inc. (IKT) had Net Income of $-19.59M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
|
Net Income |
$-19.59M |
-- |
|
-- |
|
$21.05M |
|
$-21.05M |
|
$1.46M |
|
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-21.05M |
|
$-21.05M |
|
174.57M |
|
174.57M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$162.34M |
|
-- |
|
$1.24M |
|
$163.59M |
|
$10.26M |
|
-- |
|
-- |
|
$10.26M |
|
$153.33M |
|
$153.33M |
|
$153.33M |
|
132.03M |
|
| Cash Flow Statement Financials | |
$-24.50M |
|
$-86.39M |
|
$2.88M |
|
$139.22M |
|
$31.21M |
|
$-108.01M |
|
$10.91M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.82 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-24.50M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.78% |
|
-12.78% |
|
-11.98% |
|
-12.78% |
|
$1.16 |
|
$-0.14 |
|
$-0.14 |
|